IGD is launching a new insight programme to help food companies navigate the impact of GLP-1 weight-loss medication.
The IGD Futures: GLP-1 programme will aim to help food industry businesses understand the threats and capitalise on the impacts of the drugs, amid a huge rise in uptake and growing uncertainty over how it will hit the sector.
IGD said its research showed weight-loss medication usage is rising fast, with uptake among UK adults growing from 3.1% in June 2025 to 4.2% in October – outstripping the number following a vegan diet.
It said the effects included 35% of GLP-1 users eating out less often, 69% eating fewer snacks, and 48% eating fewer meals overall.
IGD Futures: GLP-1 is designed to provide a total consumption view of current and future changes in consumer and shopper behaviours, household dynamics, and category demand.
It will also bring together insights on wider GLP-1 impacts, such as global trends and the evolving science and regulations that go with it. The programme would include diary tracking of GLP-1 users, qualitative research into behaviours and sentiments, social listening in the UK and US, and global horizon scanning of industry responses and innovation.
“Consistently, the industry tells us they need to understand who is changing, how they are changing, and where the opportunities are,” said IGD insight director Tom Wakeman.
“We have structured this programme to help businesses turn behaviour change into commercial advantage. Our unique holistic approach reveals what is shifting, why it is shifting, and what actions will unlock value. Powered by deep insight and reliable foresight, this programme projects the scale of impact so businesses can stay ahead.”
To register interest about the IGD Futures: GLP‑1 programme, email askIGD@igd.com.
No comments yet